The new prefilled pen device is available in the full range of existing doses and has the same colour coding as the syringe to distinguish between the different strengths.
It is indicated for the treatment of:
- severe recalcitrant disabling psoriasis
- severe psoriatic arthritis
- polyarthritic forms of severe active juvenile idiopathic arthritis when the response to NSAIDs has been inadequate
- active rheumatoid arthritis.
The Metoject pen device is not currently licensed for use in Crohn's disease.
Further information: Medac